Complix is focused on the discovery and development of next generation drugs based on “Alphabodies”, a novel class of biopharmaceuticals with superior therapeutic potential. Complix also announced the creation of a fully-owned subsidiary in Luxembourg to develop novel Alphabody based therapies against viral diseases in a strategic collaboration with CRP-Santé.
Download the Local Press release:
Download the International Press release:
She sees this new project as a true challenge: developing a growing and promising research unit, managing a team as well as numerous clinical research projects in the field of oncology, nutrition or cardiology.
Read the Press release about Anna CHIOTI - French Version